Pharmacokinetics of the somatostatin analog lanreotide in patients with severe chronic renal insufficiency

Clinical Pharmacology and Therapeutics

Volumn 66, Issue 5, 1999, Pages 485-491

  Barbanoj, Manel ^a,b   Antonijoan, Rosa ^a,b   Morte, Adelaida ^a,b   Ma Grinyó, Josep ^a,b   Solà, Ricard ^a,b   Vallès, Joaquim ^a,b   Peraire, Concepció ^a,b   Cordero, José A ^a,b   Muñoz, Ana ^a,b   Jané, Francesc ^a,b   Obach, Rossend ^a,b,c  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b SA LASA Laboratorios   (Spain)

^c NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; SOMATOSTATIN DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

EID: 0032749435     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)70011-1     Document Type: Article

References (23)

1. 1. Melmed S. Acromegaly. N Engl J Med 1990;322:966-77.
2. 2. Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, et al. Octreotide treatment of acromegaly: a randomized multicenter study. Ann Intern Med 1992; 117:711-8.
3. 3. Vance ML, Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide: results of the International Multicenter Acromegaly Study Group. Arch Intern Med 1991;151:1573-8.
4. 4. Morange I, de Boisvilliers F, Chanson P, Lucas B, DcWailly D, Catus F, et al. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab 1994;79:145-51.
5. 5. Kutz K, Nüesch E, Rosenthaler J. Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroenterol 1986;21(suppl 119):65-72.
6. 6. Chassard D, Barbanoj M, Catalá M, Hawkins F, Moreiro J, Picó A, et al. Pharmacokinetics of lanreotide. J Endocrinol Invest 1997;20(suppl 7):30-2.
7. 7. Giusti M, Gussoni G, Cuttica CM, Giordano G, and the Italian Multicenter Slow Release Lanreotide Study Group. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. J Endocrinol Metab 1996;81:2089-97.
8. 8. Caron P, Morange-Ramos I, Cogne M, Jaquet P. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Endocrinol Metab 1997;82:18-22.
9. 9. Lancrajan I, Bruns C, Grass P, Jaquet P, Jervell J, Kendall-Taylor P, et al. Sandostatin LAR: pharmacokinetics, pharmacodynamics, efficacy and tolerability in acromegalic patients. Metabolism 1995;44(suppl 1):18-26.
10. 10. Ikos D, Ljunggren H, Luff R. Glomerular filtration rate and renal plasma flow in acromegaly. Acta Endocrinol (Copenh) 1956;21:226-36.
11. 11. Falkheden T, Sjögren B, Extracellular fluid volume and renal function in pituitary insufficiency and acromegaly. Acta Endocrinol (Copenh) 1964;46:80-8.
12. 12. Serri O, Beauregard H, Brazeau P, Abribat T, Lambert J, Harris A, et al. Somatostatin analogue, octreotide, reduces increased glomerular filtration rate and kidney size in insulin-dependent diabetes. JAMA 1991;265:888-92.
13. 13. Dullaart RPF, Meijer S, Marbach P, Sluiter WJ. Effect of a somatostatin analogue, octreotide, on renal haemodynamics and albuminuria in acromegalic patients. Eur J Clin Invest 1992;22:494-502.
14. 14. Vora J, Owens DR, Luzio S, Atiea J, Ryder R, Hayes TM. Renal response to intravenous somatostatin in insulin-dependent diabetic patients and normal subjects. J Clin Endocrinol Metab 1987;64:975-9.
15. 15. Battershill PE, Clissold SP. Octreotide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs 1989;38:658-702.
16. 16. Sieber CC, Mosca PG, Groszman RJ. Effect of somatostatin on mesenteric vascular resistance in normal and portal hypertensive rats. Am J Physiol 1992;262:G274-7.
17. 17. Lin JH, Cocchetto DM, Duggan DE. Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs. Clin Pharmacokinet 1987;12:402-32.
18. 18. Sjöholm I, Kober A, Odar-Cederlof I, Borga O. Protein binding of drugs in uremic and normal serum: the role of endogenous binding inhibitors. Biochem Pharmacol 1976;25:1205-13.
19. 19. Verbeeck RK, de Schepper PJ. Influence of chronic renal failure and hemodialysis on diflunisal protein binding. Clin Pharmacol Ther 1980;27:628-35.
20. 20. Kallivetakis N, Yotis A, del Pozo E, Marbach P, Mountolakis T, Tolis G. Pharmacokinetics of SMS 201-995 in normal subjects and in patients with severe renal failure [abstract]. Neuroendocrinol Lett 1985;7:92.
21. 21. Polonsky KS, Jaspan JB, Berelowitz M, Emmanouel DS, Dhorajiwala J. Hepatic and renal metabolism of somatostatin-like immunoreactivity. J Clin Invest 1981; 68:1149-57.
22. 22. Sheppard M, Shapiro B, Pimstone B, Kronheim S, Berelowitz M, Gregory M. Metabolic clearance and plasma half-life disappearance time of exogenous somatostatin in man. J Clin Endocrinol Metab 1979;48: 50-3.
23. 23. Perlik F, Drazna E, Antonijoun R, Cordero JA, Cendrós JM, Barbanoj MJ. Pharmacokinetic profile of the somatostatin analogue lanreotide in moderate to severe hepatic insufficiency [abstract]. Methods Find Exp Clin Pharmacol 1998;20(suppl A):59.